ClinicalTrials.Veeva

Menu

Occurrence and Influencing Factors of Cognitive Impairment in Elderly Patients With Schizophrenia and

T

Third People's Hospital, Huzhou City, Zhejiang Province, China

Status

Completed

Conditions

Cognitive Impairment
Schizophrenia Disorders
Acceptance and Commitment Therapy

Treatments

Other: the conventional treatment group
Other: the ACT group

Study type

Interventional

Funder types

Other

Identifiers

NCT06949657
No. 2025-130

Details and patient eligibility

About

ACT combined with stratified intervention improved cognitive function and quality of life in elderly schizophrenia patients by enhancing psychological flexibility and family support.

Full description

This study analyzes factors influencing cognitive impairment and evaluates the efficacy of a stratified intervention combining Acceptance and Commitment Therapy (ACT) with these factors to improve cognitive function and quality of life. A total of 149 elderly patients with schizophrenia were enrolled, split into cognitive impairment (n = 86) and non-cognitive impairment (n = 63) groups. A combined case-control and randomized controlled trial design was employed. Logistic regression was used to identify independent risk factors. Cognitive impairment patients were randomly assigned to either the conventional treatment group (n = 39) or the ACT group (n = 39) for a 6-week intervention. Evaluation instruments included the AAQ-II (psychological flexibility), GSES (self-efficacy), FACES II-CV (family functioning), SSMI-C (internalized stigma), and SQLS (quality of life).

Enrollment

78 patients

Sex

All

Ages

60+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • (1)Meets the diagnostic criteria for schizophrenia as defined in the International Classification of Diseases, Tenth Revision (ICD-10);
  • (2) age > 60 years;
  • (3)possesses at least a primary school education, enabling independent completion of all questionnaires;
  • (4) has been taking antipsychotic medication continuously and regularly for at least one year during the enrollment period, with current symptoms and disease status stabilized in the maintenance phase;
  • (5)informed consent obtained from the patient or their family/guardian.

Exclusion criteria

  • (1) Coexisting organic mental disorders, affective disorders, or similar conditions;
  • (2) coexisting physical illnesses that may affect cognitive function, such as hepatic or renal dysfunction;
  • (3) alcohol dependence or dependence on psychoactive substances;
  • (4) receipt of electroconvulsive therapy within the past three months.

Trial design

Primary purpose

Other

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

78 participants in 2 patient groups

the conventional treatment group
Other group
Description:
Patients received conventional mental health education once weekly for 6 weeks, covering schizophrenia symptoms, treatment, and prognosis. Standard nursing care and antipsychotic medications (e.g., olanzapine, quetiapine) were maintained without additional psychological interventions.
Treatment:
Other: the conventional treatment group
the ACT group
Other group
Description:
Patients received ACT-based nursing interventions tailored to risk factors (e.g., age ≥70, long disease duration), including: ACT modules: Acceptance, cognitive defusion, mindfulness, values clarification, and committed action. Adjunct strategies: Family therapy, Tai Chi, and crisis planning. Frequency: Daily practice + 1-2 group sessions/week for 6 weeks. Goal: Enhance psychological flexibility, reduce stigma, and improve cognitive function.
Treatment:
Other: the ACT group

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems